Advanced Nanomedicine for Drug Delivery

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: 19 September 2025 | Viewed by 388

Special Issue Editors


E-Mail Website
Guest Editor
Department of Drug Science and Technology, University of Torino, Via Pietro Giuria 9, 10125 Torino, Italy
Interests: extracellular vesicles; nanoparticles; drug delivery; nanomedicine; in vitro study; nanotoxicology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Drug Science and Technology, University of Torino, Via Pietro Giuria 9, 10125 Torino, Italy
Interests: nanomedicine; nanomaterials; drug delivery; extracellular vesicle; in vitro characterization

Special Issue Information

Dear Colleagues,

In recent years, nanomedicine has been successfully assisting preclinical and clinical investigations to effectively fight cancer and infectious, inflammatory or genetic diseases by reducing deaths and improving the quality of life of patients. Nanomedicine is a branch of knowledge born from the amalgamation of sciences such as biology, medicine, pharmaceutics, chemistry, and engineering. Referring in detail to drug delivery, nanomaterials and related methods and processes provide researchers, drug technologists and clinicians with systems, molecules or new functionalization and engineering solutions capable of making increasingly effective, safe and sustainable diagnoses and treatments.

Advanced nanomedicine and customized delivery tools face issues such as poor drugs stability or bioavailability, limited targeting ability and their relationship with the patients’ immune system and physiological barriers such as the blood–brain and placental barriers, gut epithelium and skin epidermis.

Despite the many recent steps forward, much remains to be completed for the optimization of new drug formulations that meet the required healthcare industry safety and quality standards.

The purpose of this Special Issue is to collect valuable contributions, research papers or reviews on the development, characterization and engineering of new nano-enabled advanced drug delivery solutions.

Potential topics include, but are not limited to, the following:

  • Design of nanomedicine products for drug delivery;
  • In vitro, ex vivo and in vivo tests of nanomedicine products for drug delivery;
  • Engineering nanomedicine products for drug delivery applications;
  • Drug delivery nanotools for diagnostic applications;
  • Drug delivery nanotools for therapeutic applications;
  • Drug delivery nanotools for theragnostic applications;
  • Nanomedicine products for drug delivery in clinics;
  • Safety and regulatory issues of nanomedicine products for drug delivery applications.

Dr. Tania Limongi
Dr. Francesca Susa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • drug delivery
  • cancer
  • nanocarrier
  • cytotoxicity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3131 KiB  
Article
Aerosol Delivery of Hesperetin-Loaded Nanoparticles and Immunotherapy Increases Survival in a Murine Lung Cancer Model
by Sayeda Yasmin-Karim, Geraud Richards, Amanda Fam, Alina-Marissa Ogurek, Srinivas Sridhar and G. Mike Makrigiorgos
Nanomaterials 2025, 15(8), 586; https://doi.org/10.3390/nano15080586 - 11 Apr 2025
Viewed by 265
Abstract
Flavonoids, like Hesperetin, have been shown to be an ACE2 receptor agonists with antioxidant and pro-apoptotic activity and can induce apoptosis in cancer cells. ACE2 receptors are abundant in lung cancer cells. Here, we explored the application of Hesperetin bound to PegPLGA-coated nanoparticles [...] Read more.
Flavonoids, like Hesperetin, have been shown to be an ACE2 receptor agonists with antioxidant and pro-apoptotic activity and can induce apoptosis in cancer cells. ACE2 receptors are abundant in lung cancer cells. Here, we explored the application of Hesperetin bound to PegPLGA-coated nanoparticles (Hesperetin nanoparticles, HNPs) and anti-CD40 antibody as an aerosol treatment for lung tumor-bearing mice. The Hesperetin nanoparticles (HNPs) were engineered using a nano-formulation microfluidic technique and polymeric nanoparticles. The in vitro studies were performed in human A549 (ATCC) and murine LL/2-Luc2 (ATCC) lung cancer cell lines. A syngeneic orthotopic murine model of lung cancer was generated in wild (+/+) C57/BL6 background mice with luciferase-positive cell line LL/2-Luc2 cells. Lung tumor-bearing mice were treated via aerosol inhalation with HNP, anti-CD40 antibody, or both. Survival was used to analyze the efficacy of the aerosol treatment. The cohorts were also analyzed for body condition score, weight, and liver and kidney function. Analysis of an orthotopic murine lung cancer model demonstrated a differential uptake of the HNPs and anti-CD40 by the cancer cells. A higher survival rate was observed when the combination of aerosol treatment with HNPs was added with the treatment with anti-CD40 (p < 0.001), as compared to anti-CD40 alone (p < 0.01). Moreover, two tumor-bearing mice survived long-term with the combination treatment, and their tumors were diminished. Subsequently, these two mice were shown to be refractory to the development of subcutaneous tumors, indicating systemic resilience to developing new tumors. Using an inhalation-based administration, we successfully established a treatment model of increased therapeutic efficacy with HNPs and anti-CD40 in an orthotopic murine lung cancer model. Our findings open the possibility of improved lung cancer treatment using nanoparticles like flavonoids and immunoadjuvants. Full article
(This article belongs to the Special Issue Advanced Nanomedicine for Drug Delivery)
Show Figures

Figure 1

Back to TopTop